Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
594 Views
eMediNexus 06 October 2021
AstraZeneca has sought emergency approval from U.S. regulators for its antibody cocktail for protection against COVID-19.
AstraZeneca′s biotech compound, called AZD7442, contains lab-developed antibodies that can persist in the body for months to check the virus in there is an infection. The treatment, created to last for several months to about one year, could provide protection to those who do not have a strong immune response to COVID-19 vaccines, which could be due to, chemotherapy or drugs given after organ transplants, among other causes.
The drug, which is administered in two injections, could also act as a supplement to vaccination course for individuals who need to boost their protection further, stated the company… (Reuters, October 5, 2021)
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}